Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28,495,649
-
Total 13F shares
-
4,410,134
-
Share change
-
+509,039
-
Total reported value
-
$33,296,650
-
Price per share
-
$7.55
-
Number of holders
-
28
-
Value change
-
+$3,970,096
-
Number of buys
-
10
-
Number of sells
-
12
Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q3 2017
As of 30 Sep 2017,
Oncocyte Corporation - Common Shares, No Par Value (OCX) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,410,134 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, BlackRock Inc., Artal Group S.A., BRIDGEWAY CAPITAL MANAGEMENT INC, VANGUARD GROUP INC, NORTHERN TRUST CORP, Destination Wealth Management, GEODE CAPITAL MANAGEMENT, LLC, Family Management Corp, and Bank of New York Mellon Corp.
This page lists
28
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.